期刊文献+

细胞因子诱导的杀伤细胞局部治疗脑胶质瘤的临床研究 被引量:2

Clinical study on local treatment of glioma by killing cells induced by cytollines
下载PDF
导出
摘要 目的观察CIK细胞局部治疗脑恶性胶质瘤的不良反应和初步疗效,探索治疗脑恶性胶质瘤的新方法。方法神经外科显微镜下尽量彻底切除肿瘤,术中行快速冰冻,对病理为恶性(WHO分类Ⅲ级以上)并符合其他条件的6例埋置Ommaya储液囊;术后患者常规先行放射治疗;放疗结束后先化疗2个疗程;然后进行局部免疫治疗。治疗期间严密观察并记录患者的症状及体征,根据不良反应判断其对治疗的耐受性;治疗前后行头颅MR检查并随访患者的生存情况,初步判断治疗的疗效。结果有6例患者共接受10个疗程CIK细胞局部治疗。随访7~24个月,随访率100%。不良反应:发热2例4个疗程,头痛3例4个疗程,失语1例,肢体肌力下降1例,分别用物理降温、甘露醇脱水、加用镇痛药等对症治疗好转。疗效:本组自首次CIK细胞治疗至随访终点平均生存期12.5个月。6例中2例CR,1例PR,1例SD,2例PD。结论脑恶性胶质瘤CIK细胞局部免疫治疗不良反应轻,对症处理均能缓解;在严格掌握适应证的前提下,该方法安全,患者能够耐受,并初步显示部分病例有一定疗效;对常规治疗手段失败的患者可以选择这一措施。
出处 《广东医学》 CAS CSCD 北大核心 2005年第9期1188-1190,共3页 Guangdong Medical Journal
基金 华南肿瘤学国家重点实验室基金(编号:985-Ⅱ) 广东省自然科学基金资助项目(编号:31721)
  • 相关文献

参考文献13

  • 1夏建川 曾益新.肿瘤生物和基因治疗的研究进展[A]..中国肿瘤临床年鉴[C].中国铁道出版社,2003.15-19.
  • 2Dillman RO, Duma CM, Schiltz PM. et al. Intracavitary placement of autologous lymphokine - activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother, 2004, 27(5): 398.
  • 3林丽,陈忠平.细胞因子诱导的杀伤细胞体外抗胶质瘤的实验研究[J].中国神经肿瘤杂志,2003,1(2):69-72. 被引量:8
  • 4Mahaley MS, Brooks WH, Roszman TL, et al. Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain - tumor patients. J Neurosurg, 1977, 46: 467.
  • 5Elliott LH, Brooks WH, Roszman TL. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. J Immunol, 1984, 132:1208.
  • 6Korshunov A, Golanov A, Sycheva R, et al. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. Cancer, 2004,100(6): 1230.
  • 7Schaardenbubg D, Van Denbrink HR, Wieringa HJ. Short - term steroid therapy, sometimes with long- term sequelae. Ned Tijdschr Geneeskd,2001,145(370): 1769.
  • 8Vachon P, Moreau JP. Low doses of dexamethasone decreas brain water content of collagenase - induced cerebral hematoma. Can J Vet Res,2003, 67(2): 157.
  • 9Tehranian R, Andell - Jonsson S, Beni SM, et al. Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin - 1 receptor antagonist. J Neuro Trauma, 2002, 19 (8): 939.
  • 10Hayes RL,Arbit E,Odaimi M,et al. Adoptive cellular immunotherapy for the reatment of malignant gliomas. Critical Reviews in Oncology/Hematology,2001,39: 31.

二级参考文献10

  • 1G. D. Schmidt-Wolf,R. S. Negrin,I. G. H. Schmidt-Wolf.Activated T cells and cytokine-induced CD3+CD56+ killer cells[J]. Annals of Hematology . 1997 (2)
  • 2Schmidt-Wolf IG,Lefterova P,Mehta BA, et al.Phenotypic Characterization and identification of effecter cells involved in tumor cell recognition of cytokine-induced killer cells. Experimental Hematology . 1993
  • 3Schmidt-Wolf IG,Finke S,Trojaneck B, et al.Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. British Journal of Cancer . 1999
  • 4Scheffold C,Brandt K,Johnston V, et al.Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplantation . 1995
  • 5Zoll B,Lefterova P,Ebert O, et al.Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation. Cytokine . 2000
  • 6Ochoa AC,Hasz DE,Rezonzew R, et al.Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2:identification and isolation of effector aubsets. Cancer Research . 1989
  • 7Schmidt-Wolf GH,Negrin RS,Kiem HP,et al.Use of SCID mouse/human lymphoma model to evaluate cytokine induced killer cells with potent anti-tumor cell activity. Journal of Experimental Medicine, The . 1991
  • 8Schmidt-Wolf GD,Negrin RS,Schmidt-Wolf IG.Activated T cells and cytokine-induced CD3+ CD56+ killer cells. Annals of Hematology . 1997
  • 9Schmidt-Wolf IGH,Lefterova P,Johnston V,et al.Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cellular Immunology . 1996
  • 10于津浦,任秀宝,郝希山.CIK细胞-肿瘤过继免疫治疗的新希望[J].中国肿瘤临床,2001,28(7):557-560. 被引量:35

共引文献7

同被引文献10

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部